345 related articles for article (PubMed ID: 12015594)
1. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
[TBL] [Abstract][Full Text] [Related]
2. Amyloid diseases: small drugs lead the attack.
Iversen L
Nature; 2002 May; 417(6886):231-3. PubMed ID: 12015581
[No Abstract] [Full Text] [Related]
3. Drug targets for amyloidosis.
Kolstoe SE; Wood SP
Biochem Soc Trans; 2010 Apr; 38(2):466-70. PubMed ID: 20298204
[TBL] [Abstract][Full Text] [Related]
4. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
Gillmore JD; Tennent GA; Hutchinson WL; Gallimore JR; Lachmann HJ; Goodman HJ; Offer M; Millar DJ; Petrie A; Hawkins PN; Pepys MB
Br J Haematol; 2010 Mar; 148(5):760-7. PubMed ID: 20064157
[TBL] [Abstract][Full Text] [Related]
5. [Novel therapeutic approach to amyloidosis: no implications as yet for patients with Alzheimer's disease].
Lemstra AW; Eikelenboom P; Meijer EW; van Gool WA
Ned Tijdschr Geneeskd; 2002 Sep; 146(37):1720-3. PubMed ID: 12357871
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP.
Hohenester E; Hutchinson WL; Pepys MB; Wood SP
J Mol Biol; 1997 Jun; 269(4):570-8. PubMed ID: 9217261
[TBL] [Abstract][Full Text] [Related]
7. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.
Baltz ML; Caspi D; Evans DJ; Rowe IF; Hind CR; Pepys MB
Clin Exp Immunol; 1986 Dec; 66(3):691-700. PubMed ID: 3568456
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
Richards DB; Cookson LM; Berges AC; Barton SV; Lane T; Ritter JM; Fontana M; Moon JC; Pinzani M; Gillmore JD; Hawkins PN; Pepys MB
N Engl J Med; 2015 Sep; 373(12):1106-14. PubMed ID: 26176329
[TBL] [Abstract][Full Text] [Related]
9. [At last new light for the treatment of amyloidosis].
Pettersson T
Duodecim; 2003; 119(12):1097-8. PubMed ID: 12868354
[No Abstract] [Full Text] [Related]
10. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
Pepys MB
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
[TBL] [Abstract][Full Text] [Related]
11. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.
Kolstoe SE; Ridha BH; Bellotti V; Wang N; Robinson CV; Crutch SJ; Keir G; Kukkastenvehmas R; Gallimore JR; Hutchinson WL; Hawkins PN; Wood SP; Rossor MN; Pepys MB
Proc Natl Acad Sci U S A; 2009 May; 106(18):7619-23. PubMed ID: 19372378
[TBL] [Abstract][Full Text] [Related]
12. Structure of pentameric human serum amyloid P component.
Emsley J; White HE; O'Hara BP; Oliva G; Srinivasan N; Tickle IJ; Blundell TL; Pepys MB; Wood SP
Nature; 1994 Jan; 367(6461):338-45. PubMed ID: 8114934
[TBL] [Abstract][Full Text] [Related]
13. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
Maeda S
Amyloid; 2003 Aug; 10 Suppl 1():17-20. PubMed ID: 14640037
[TBL] [Abstract][Full Text] [Related]
14. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen.
Noursadeghi M; Bickerstaff MC; Gallimore JR; Herbert J; Cohen J; Pepys MB
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14584-9. PubMed ID: 11121061
[TBL] [Abstract][Full Text] [Related]
15. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease.
Hawkins PN; Rossor MN; Gallimore JR; Miller B; Moore EG; Pepys MB
Biochem Biophys Res Commun; 1994 Jun; 201(2):722-6. PubMed ID: 7516157
[TBL] [Abstract][Full Text] [Related]
16. Amyloidosis: a clinico-pathophysiological synopsis.
Hirschfield GM
Semin Cell Dev Biol; 2004 Feb; 15(1):39-44. PubMed ID: 15036205
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.
Al-Shawi R; Tennent GA; Millar DJ; Richard-Londt A; Brandner S; Werring DJ; Simons JP; Pepys MB
Open Biol; 2016 Feb; 6(2):150202. PubMed ID: 26842068
[TBL] [Abstract][Full Text] [Related]
18. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
Richards DB; Cookson LM; Barton SV; Liefaard L; Lane T; Hutt DF; Ritter JM; Fontana M; Moon JC; Gillmore JD; Wechalekar A; Hawkins PN; Pepys MB
Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298867
[TBL] [Abstract][Full Text] [Related]
19. The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.
Pepys MB
Front Immunol; 2018; 9():2382. PubMed ID: 30459761
[TBL] [Abstract][Full Text] [Related]
20. Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer's disease.
Rostagno A; Lashley T; Ng D; Meyerson J; Braendgaard H; Plant G; Bojsen-Møller M; Holton J; Frangione B; Revesz T; Ghiso J
J Neurol Sci; 2007 Jun; 257(1-2):88-96. PubMed ID: 17374542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
